In this guide, well break down: The dosing ranges studied so far (112 mg per week) How dosing progression impacts weight loss and tolerability Key differences between Retatrutide dosing and other GLP-1/GIP agonists What the future may hold for clinical and real-world use Table of contents What Is Retatrutide
At PEAK, GLP-1 medication is never the entire treatment plan
hordei (Dudler et al., GstA1 gene, which encodes a 29 kD GST protein (GST29) was specifically inducible by fungal infections and exogenous GSH, but not by various xenobiotics that typically induce GST activity (paraquat, atrazine, alachlor, metolachlor) (Mauch and Dudler, 1993)
Genetic insight does not predict exact medication response, but it can support more informed provider conversations
PeptIQ is built for exactly this
Today, the majority of the emerging GIP receptor targeting compounds are claimed to be agonists, and to increase insulin secretion (17, 20), to improve insulin sensitivity (91), and also, suppress appetite (119)